Gök, V. Et Al. 2023. Immunodeficiency associated with a novel functionally defective variant of SLC19A1 benefits from folinic acid treatment. GENES AND IMMUNITY , vol.24, no.1 , 12-20.

Gök, V., Erdem, Ş., Haliloğlu, Y., Bişgin, A., Belkaya, S., Başaran, K. E., ... Canatan, M. F.(2023). Immunodeficiency associated with a novel functionally defective variant of SLC19A1 benefits from folinic acid treatment. GENES AND IMMUNITY , vol.24, no.1, 12-20.

Gök, VEYSEL Et Al. "Immunodeficiency associated with a novel functionally defective variant of SLC19A1 benefits from folinic acid treatment," GENES AND IMMUNITY , vol.24, no.1, 12-20, 2023

Gök, VEYSEL Et Al. "Immunodeficiency associated with a novel functionally defective variant of SLC19A1 benefits from folinic acid treatment." GENES AND IMMUNITY , vol.24, no.1, pp.12-20, 2023

Gök, V. Et Al. (2023) . "Immunodeficiency associated with a novel functionally defective variant of SLC19A1 benefits from folinic acid treatment." GENES AND IMMUNITY , vol.24, no.1, pp.12-20.

@article{article, author={VEYSEL GÖK Et Al. }, title={Immunodeficiency associated with a novel functionally defective variant of SLC19A1 benefits from folinic acid treatment}, journal={GENES AND IMMUNITY}, year=2023, pages={12-20} }